Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,570

Employees7,570

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,570

Employees7,570

BIIB Key Statistics

Market cap

20.49B

Market cap20.49B

Price-Earnings ratio

12.70

Price-Earnings ratio12.70

Dividend yield

—

Dividend yield—

Average volume

1.27M

Average volume1.27M

High today

$143.50

High today$143.50

Low today

$140.06

Low today$140.06

Open price

$142.67

Open price$142.67

Volume

1.15M

Volume1.15M

52 Week high

$252.17

52 Week high$252.17

52 Week low

$140.05

52 Week low$140.05

BIIB News

Seeking Alpha 3d

Sage sues Biogen in wake of $469M buyout offer: report

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid v...

Seeking Alpha 6d

Sarepta, Biogen drugs with accelerated approval under fire in FDA report

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using tr...

Simply Wall St 6d

This Biogen Insider Increased Their Holding In The Last Year

From what we can see, insiders were net buyers in Biogen Inc.'s ( ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they...

Analyst ratings

53%

of 36 ratings

Buy

52.8%

Hold

47.2%

Sell

More BIIB News

Benzinga 6d

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

On Monday, the FDA accepted Eisai Co., Ltd. ESALY and Biogen Inc’s BIIB Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinject...

Seeking Alpha 7d

Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an in...